Current landscape of personalized medicine adoption and implementation in Southeast Asia

• Published in: BMC medical genomics Vol. 11; no. 1; p. 94
• Main Authors: Chong, Huey Yi, Allotey, Pascale A, Chaiyakunapruk, Nathorn
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26.10.2018; BioMed Central; BMC
• Subjects: Decision making; Developing countries; Forecasts and trends; Genomics; Health care; Implementation; LDCs; Management; Medical care quality; Medical research; Medical screening; Personalized medicine; Pharmacogenomics; Precision medicine; Public health administration; Southeast Asia; Stakeholders; Studies; Southeast Asia; Singapore; United Kingdom > UK; United States > US; Malaysia; Thailand; Indonesia; Southeast Asia; Personalized medicine; Implementation; Pharmacogenomics
• ISSN: 1755-8794; 1755-8794
• DOI: 10.1186/s12920-018-0420-4

The emergence of personalized medicine (PM) has raised some tensions in healthcare systems. PM is expensive and health budgets are constrained - efficient healthcare delivery is therefore critical. Notwithstanding the cost, many countries have started to adopt this novel technology, including resource-limited Southeast Asia (SEA) countries. This study aimed to describe the status of PM adoption in SEA, highlight the challenges and to propose strategies for future development. The study included scoping review and key stakeholder interviews in four focus countries - Indonesia, Malaysia, Singapore, and Thailand. The current landscape of PM adoption was evaluated based on an assessment framework of six key themes - healthcare system, governance, access, awareness, implementation, and data. Six PM programs were evaluated for their financing and implementation mechanisms. The findings revealed SEA has progressed in adopting PM especially Singapore and Thailand. A regional pharmacogenomics research network has been established. However, PM policies and programs vary significantly. As most PM programs are champion-driven and the available funding is limited, the current PM distribution has the potential to widen existing health disparities. Low PM awareness in the society and the absence of political support with financial investment are fundamental barriers. There is a clear need to broaden opportunities for critical discourse about PM especially for policymakers. Multi-stakeholder, multi-country strategies need to be prioritized in order to leverage resources and expertise. Adopting PM remains in its infancy in SEA. To achieve an effective PM adoption, it is imperative to balance equity issues across diverse populations while improving efficiency in healthcare.